Comprehensive clinical and molecular portraits of grade 3 ER+ HER-breast cancer

被引：1
|
作者：
Wang, K. [1 ]
Franch-Exposito, S. [2 ]
Li, L. [3 ]
Xiang, T. [4 ]
Wu, J. [3 ]
Ren, G. [4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China
[2] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Gastrointestinal & Pancreat Oncol Team, Barcelona, Spain
[3] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[4] Chongqing Med Univ, Affiliated Hosp 1, Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
34P
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] The Future of ER+/HER2-Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
    Stravodimou, Athina
    Voutsadakis, Ioannis A.
    ANTICANCER RESEARCH, 2020, 40 (09) : 4829 - 4841
  • [42] Pre-clinical study of amcenestrant and HER2-targeted therapies in HER2+/ER+ breast cancer cell line models
    Mahdi, Amira F.
    Ashfield, Niall
    Conlon, Neil T.
    Crown, John
    Collins, Denis M.
    CANCER RESEARCH, 2023, 83 (05)
  • [43] Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
    Shuai Li
    Jiayi Wu
    Ou Huang
    Jianrong He
    Li Zhu
    Weiguo Chen
    Yafen Li
    Xiaosong Chen
    Kunwei Shen
    BMC Cancer, 21
  • [44] HER2−/ER+-Brustkrebs: fehlende Taxoleffektivität?HER2−/ER+ breast cancer: lack of effectiveness of taxol?
    N. Bangemann
    Der Onkologe, 2008, 14 (2): : 198 - 200
  • [45] Predicting benefit from HER2-targeted therapies in patients with ER+/HER2+breast cancer
    Turnbull, A. K.
    Webber, V.
    McStay, D.
    Arthur, L.
    Martinez-Perez, C.
    Fernando, A.
    Renshaw, L.
    Keys, J.
    Clarke, R.
    Sims, A. H.
    Dixon, J. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [46] Estimating the cost of adjuvant chemotherapy in ER+/HER2-early breast cancer and distant recurrence of breast cancer in the UK
    Berdunov, V.
    Millen, S.
    Paramore, A.
    Reynia, S.
    Fryer, N.
    Griffin, J.
    Georges, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S46 - S46
  • [47] Role of endocrine therapy in ER+/HER2(+) breast cancers
    Webber, Victoria L.
    Dixon, J. Michael
    BREAST CANCER MANAGEMENT, 2014, 3 (01) : 103 - 111
  • [48] Complex rearrangements fuel ER+ and HER2+ breast tumours
    Kathleen E. Houlahan
    Lise Mangiante
    Cristina Sotomayor-Vivas
    Alvina Adimoelja
    Seongyeol Park
    Aziz Khan
    Sophia J. Pribus
    Zhicheng Ma
    Jennifer L. Caswell-Jin
    Christina Curtis
    Nature, 2025, 638 (8050) : 510 - 518
  • [49] Comprehensive molecular portraits of human breast tumours
    Koboldt, Daniel C.
    Fulton, Robert S.
    McLellan, Michael D.
    Schmidt, Heather
    Kalicki-Veizer, Joelle
    McMichael, Joshua F.
    Fulton, Lucinda L.
    Dooling, David J.
    Ding, Li
    Mardis, Elaine R.
    Wilson, Richard K.
    Ally, Adrian
    Balasundaram, Miruna
    Butterfield, Yaron S. N.
    Carlsen, Rebecca
    Carter, Candace
    Chu, Andy
    Chuah, Eric
    Chun, Hye-Jung E.
    Coope, Robin J. N.
    Dhalla, Noreen
    Guin, Ranabir
    Hirst, Carrie
    Hirst, Martin
    Holt, Robert A.
    Lee, Darlene
    Li, Haiyan I.
    Mayo, Michael
    Moore, Richard A.
    Mungall, Andrew J.
    Pleasance, Erin
    Robertson, A. Gordon
    Schein, Jacqueline E.
    Shafiei, Arash
    Sipahimalani, Payal
    Slobodan, Jared R.
    Stoll, Dominik
    Tam, Angela
    Thiessen, Nina
    Varhol, Richard J.
    Wye, Natasja
    Zeng, Thomas
    Zhao, Yongjun
    Birol, Inanc
    Jones, Steven J. M.
    Marra, Marco A.
    Cherniack, Andrew D.
    Saksena, Gordon
    Onofrio, Robert C.
    Pho, Nam H.
    NATURE, 2012, 490 (7418) : 61 - 70
  • [50] Comprehensive molecular portraits of human breast tumours
    Nature, 2012, 490 : 61 - 70
12345